You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Drug Delivery Method for Sudden Sensorineural Hearing Loss

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): The ultimate goal of the proposed project is to evaluate and commercialize a combination of proprietary magnet assemblies and magnetic nanoparticles (initially developed by our University STTR partner), that has been shown in preliminary animal studies to improve delivery of medications to the inner ear. Initial animal studies using the system (which uses magne ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional propertieslimit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcriptional activities have been previously shown to ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors

    SBC: HocusLocus Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): We propose developing a trans-molecular RNA-switch for scientists to negatively affect the activity of endogenous microRNA for use as a molecular tool or therapeutic, an anti-miR. Since the discovery of miRNA, the creation of effective anti-miRs has been important, first to study and verify miRNA interactions, and, secondly, as a therapeutic tool. But, creating ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Image-guided planning system for skull correction in children with craniosynostos

    SBC: KITWARE INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Development of IPdR for Radiosensitization Period of Performance: 09/19/2014- 06/18/2015

    SBC: Shuttle Pharmaceuticals, Inc.            Topic: NCI

    The objective of this fast-track SBIR Application is to advance commercialization efforts for IPdR (5-iodo-2pyrimidinone-2'-deoxyribose), a prod rug of the radiosensitizer IUdR (5-iodo-2'-deoxyuridine). In the Phase I SBIR, we will determine the scientific merit, feasibility and potential for commercialization of oral lPdR as a radiation sensitizer for use in cancer treatment. Administrative tasks ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. OTHER FUNCTION- Cell-free production of site-specifically phosphorylated proteins

    SBC: Rana Bioscience, Inc.            Topic: NCI

    Not Available

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government